Thanos Zomas, MD, from Takeda Oncology, discusses follow-up data from the ECHELON-1 study presented at ASH 2020.
The ECHELON-1 study was an open-label, randomized, phase 3 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma. The trial finished in 2017.
Hodgkin lymphoma is a rare monoclonal lymphoid neoplasm that is usually treated with autologous stem cell transplant or high-dose chemotherapy. In stage 3 Hodgkin lymphoma, the lymphoma is found in lymph node areas on both sides of the diaphragm or above the diaphragm and in the spleen. In stage 4 Hodgkin lymphoma, it has spread into at least one organ outside of the lymph system.
The primary objective of the ECHELON-1 study was comparing modified progression-free survival (mPFS) obtained with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus that obtained with doxorubicin, bleomycin, vinblastine, and dacarbazine. The results found a significant benefit for those patients receiving brentuximab vedotin.
The follow-up data presented at ASH 2020, representing a median follow-up of over 55 months, supported the results of the original study, suggesting that the addition of brentuximab vedotin is beneficial for those recently diagnosed with late-stage Hodgkin lymphoma.
For more information about Hodgkin lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/
